A client who suffers from severe persistent allergic asthma is prescribed omalizumab (Xolair). Which statement below correctly describes the mechanism of action associated with omalizumab (Xolair)?

Inhibits the production of leukotrienes and histamine, preventing further asthma attacks.

Inhibits mast cells from releasing histamine, preventing further asthma attacks

Selectively binds to IgE, reducing allergic mediators and asthma attacks.

Stimulates alpha-adrenergic receptors to assist in reduction of allergic related symptoms.